Timber Pharmaceuticals Stock Forecast, Price & News

+0.04 (+3.15 %)
(As of 06/11/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.35 million shs
Average Volume1.19 million shs
Market Capitalization$48.26 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive TMBR News and Ratings via Email

Sign-up to receive the latest news and ratings for Timber Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Timber Pharmaceuticals logo

About Timber Pharmaceuticals

Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical dermatology company, focused on the development and commercialization of treatments for orphan dermatologic diseases. The company was founded in 2019 and is headquartered in Basking Ridge, New Jersey.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.00 out of 5 stars

Medical Sector

1130th out of 2,099 stocks

Pharmaceutical Preparations Industry

515th out of 831 stocks

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Timber Pharmaceuticals (NASDAQ:TMBR) Frequently Asked Questions

What stocks does MarketBeat like better than Timber Pharmaceuticals?

Wall Street analysts have given Timber Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Timber Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Timber Pharmaceuticals' earnings last quarter?

Timber Pharmaceuticals, Inc. (NASDAQ:TMBR) posted its quarterly earnings results on Tuesday, March, 23rd. The company reported ($0.79) earnings per share for the quarter. The business earned $0.10 million during the quarter.
View Timber Pharmaceuticals' earnings history

Who are Timber Pharmaceuticals' key executives?

Timber Pharmaceuticals' management team includes the following people:
  • Mr. John Koconis M.B.A., Chairman, CEO & Pres (Age 50, Pay $507.26k)
  • Mr. Joseph Lucchese, Exec. VP & CFO (Age 53, Pay $360.2k)
  • Mr. Zachary Rome, COO, Exec. VP, Sec. & Director (Age 36, Pay $300.67k)
  • Dr. Alan Mendelsohn M.D., Chief Medical Officer (Age 58)

Who are some of Timber Pharmaceuticals' key competitors?

What other stocks do shareholders of Timber Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Timber Pharmaceuticals investors own include Akorn (AKRXQ), Akers Biosciences (AKER), Akebia Therapeutics (AKBA), Adamis Pharmaceuticals (ADMP), ADMA Biologics (ADMA), Acasti Pharma (ACST), AcelRx Pharmaceuticals (ACRX), Acorda Therapeutics (ACOR), Aurora Cannabis (ACB) and Ambev (ABEV).

What is Timber Pharmaceuticals' stock symbol?

Timber Pharmaceuticals trades on the NASDAQ under the ticker symbol "TMBR."

Who are Timber Pharmaceuticals' major shareholders?

Timber Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Jane Street Group LLC (0.12%), Geode Capital Management LLC (0.08%), Citadel Advisors LLC (0.07%), Citadel Advisors LLC (0.07%) and Bank of New York Mellon Corp (0.07%).
View institutional ownership trends for Timber Pharmaceuticals

Which major investors are buying Timber Pharmaceuticals stock?

TMBR stock was acquired by a variety of institutional investors in the last quarter, including Jane Street Group LLC, Geode Capital Management LLC, Citadel Advisors LLC, Citadel Advisors LLC, and Bank of New York Mellon Corp.
View insider buying and selling activity for Timber Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Timber Pharmaceuticals?

Shares of TMBR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Timber Pharmaceuticals' stock price today?

One share of TMBR stock can currently be purchased for approximately $1.31.

How much money does Timber Pharmaceuticals make?

Timber Pharmaceuticals has a market capitalization of $48.26 million and generates $450,000.00 in revenue each year.

How many employees does Timber Pharmaceuticals have?

Timber Pharmaceuticals employs 6 workers across the globe.

What is Timber Pharmaceuticals' official website?

The official website for Timber Pharmaceuticals is

Where are Timber Pharmaceuticals' headquarters?

Timber Pharmaceuticals is headquartered at 50 TICE BLVD SUITE A26, WOODCLIFF LAKE NJ, 07677.

How can I contact Timber Pharmaceuticals?

Timber Pharmaceuticals' mailing address is 50 TICE BLVD SUITE A26, WOODCLIFF LAKE NJ, 07677. The company can be reached via phone at 973 314 9570 or via email at [email protected]

This page was last updated on 6/13/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.